Business
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiM
About this update from Mimedx Group, Inc
[{"type":"image","alt":"MiMedx Group, Inc","displaySize":"","headline":null,"caption":"MiMedx Group, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/68d7327cd549087791cd3ae0959a08d8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rBfOVX0mkTKRtauLSHXfWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/68d7327cd549087791cd3ae0959a08d8","width":300,"height":120}},"lazy":false},{"type":"text","content":"Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year","length":82,"tagName":"p"},{"type":"text","content":"Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively","length":94,"tagName":"p"},{"type":"text","content":"Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales","length":68,"tagName":"p"},{"type":"text","content":"Company Estimates 2026 Net Sales in a Range of $340-360 Million","length":63,"tagName":"p"},{"type":"text","content":"Announces $100 Million Share Repurchase Program Authorization","length":61,"tagName":"p"},{"type":"text","content":"Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET","length":74,"tagName":"p"},{"type":"text","content":"MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and full year 2025.","length":202,"tagName":"p"},{"type":"text","content":"Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "MIMEDX delivered a record year of revenue and profitability in 2025, with fourth quarter results that included net sales growth of 27% year-over-year, net income of $15 million, an Adjusted EBITDA margin of 25% of net sales, and robust free cash flow. These results were driven by strong double-digit contributions in both Wound and Surgical, which grew 28% and 25%, respectively, reflecting exceptional commercial execution across the markets we serve. We were particularly pleased with the durable double-digit growth seen in Surgical, and we are keenly focused on the untapped clinical opportunities for our current and future products."","length":712,"tagName":"p"},{"type":"text","content":"Mr. Capper continued, "Looking ahead to 2...